ARDX Ardelyx Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ARDX

Price (delayed)

$5.27

Market cap

$1.3B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.24

Enterprise value

$1.48B

?
Relative Growth: Rel. Growth: 51
Relative Strength: Rel. Strength: 33
Relative Valuation: Rel. Valuation: 17
Relative Profitability: Rel. Profitability: 37

Ardelyx is focused on discovering, developing, and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is advancing tenapanor, a novel product candidate ...

Highlights
The company's gross profit rose by 29% YoY and by 8% QoQ
The company's revenue rose by 18% YoY and by 5% QoQ
Ardelyx's equity has decreased by 11% QoQ but it has increased by 2% YoY
The EPS has declined by 9% year-on-year but it has increased by 8% since the previous quarter
Ardelyx's debt has increased by 34% YoY
The company's quick ratio fell by 23% QoQ and by 15% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ardelyx.com
Peers: OPK AMGN ABT AZN

Key stats

What are the main financial stats of ARDX

ARDX stock price

How has the Ardelyx stock price performed over time
Intraday
2.13%
1 week
-13.04%
1 month
-4.53%
1 year
25.78%
YTD
-9.61%
QTD
3.33%

Financial performance

How have Ardelyx's revenue and profit performed over time
Revenue
$427.68M
Gross profit
$395.63M
Operating income
-$37.42M
Net income
-$58.06M
Gross margin
92.5%
Net margin
-13.6%
The company's gross profit rose by 29% YoY and by 8% QoQ
ARDX's operating margin is up by 21% year-on-year and by 14% since the previous quarter
The company's revenue rose by 18% YoY and by 5% QoQ
Ardelyx's net margin has increased by 10% QoQ and by 9% YoY

Price vs fundamentals

How does ARDX's price correlate with its fundamentals

Growth

What is Ardelyx's growth rate over time

Valuation

What is Ardelyx stock price valuation
P/E
N/A
P/B
8.7
P/S
3.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.46
The EPS has declined by 9% year-on-year but it has increased by 8% since the previous quarter
ARDX's P/B is 34% above its 5-year quarterly average of 6.5 and 3.6% above its last 4 quarters average of 8.4
Ardelyx's equity has decreased by 11% QoQ but it has increased by 2% YoY
The price to sales (P/S) is 70% lower than the 5-year quarterly average of 10.2 and 5% lower than the last 4 quarters average of 3.2
The company's revenue rose by 18% YoY and by 5% QoQ

Efficiency

How efficient is Ardelyx business performance
The company's return on invested capital rose by 31% YoY and by 15% QoQ
The return on sales has increased by 19% year-on-year and by 14% since the previous quarter
Ardelyx's ROA has increased by 14% YoY and by 10% from the previous quarter
Ardelyx's ROE has decreased by 11% YoY but it has increased by 6% from the previous quarter

Dividends

What is ARDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARDX.

Financial health

How did Ardelyx financials performed over time
ARDX's total assets is 42% greater than its total liabilities
ARDX's total liabilities is up by 35% year-on-year and by 6% since the previous quarter
The company's quick ratio fell by 23% QoQ and by 15% YoY
Ardelyx's debt is 40% higher than its equity
Ardelyx's debt has increased by 34% YoY
Ardelyx's debt to equity has increased by 32% YoY and by 12% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.